279 related articles for article (PubMed ID: 34205272)
1. Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness.
Moreira J; Almeida J; Saraiva L; Cidade H; Pinto M
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205272
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
4. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
5. Isoliquiritigenin inhibits the proliferation of human renal carcinoma Caki cells through the ROS-mediated regulation of the Jak2/STAT3 pathway.
Kim DH; Park JE; Chae IG; Park G; Lee S; Chun KS
Oncol Rep; 2017 Jul; 38(1):575-583. PubMed ID: 28560439
[TBL] [Abstract][Full Text] [Related]
6. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
7. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
8. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
9. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
10. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
Stoll R; Renner C; Hansen S; Palme S; Klein C; Belling A; Zeslawski W; Kamionka M; Rehm T; Mühlhahn P; Schumacher R; Hesse F; Kaluza B; Voelter W; Engh RA; Holak TA
Biochemistry; 2001 Jan; 40(2):336-44. PubMed ID: 11148027
[TBL] [Abstract][Full Text] [Related]
11. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
[TBL] [Abstract][Full Text] [Related]
12. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
13. Novel p-Functionalized Chromen-4-on-3-yl Chalcones Bearing Astonishing Boronic Acid Moiety as MDM2 Inhibitor: Synthesis, Cytotoxic Evaluation and Simulation Studies.
Bhatia RK; Singh L; Garg R; Kaur M; Yadav M; Madan J; Kancherla S; Pissurlenkar RRS; Coutinho EC
Med Chem; 2020; 16(2):212-228. PubMed ID: 31146672
[TBL] [Abstract][Full Text] [Related]
14. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
15. Resistance acquisition to MDM2 inhibitors.
Cinatl J; Speidel D; Hardcastle I; Michaelis M
Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
[TBL] [Abstract][Full Text] [Related]
16. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
Weber L
Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
[TBL] [Abstract][Full Text] [Related]
17. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
18. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
19. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
Li H; Cai X; Yang X; Zhang X
Eur J Med Chem; 2024 Jun; 272():116506. PubMed ID: 38761584
[TBL] [Abstract][Full Text] [Related]
20. Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer.
Bhatia N; Khator R; Kulkarni S; Singh Y; Kumar P; Thareja S
Curr Med Chem; 2023; 30(32):3668-3701. PubMed ID: 37190755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
